HRS-6093
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced KRAS G12D Mutant Solid Tumors
Conditions
Advanced KRAS G12D Mutant Solid Tumors
Trial Timeline
Sep 16, 2025 → Dec 1, 2028
NCT ID
NCT07134998About HRS-6093
HRS-6093 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Advanced KRAS G12D Mutant Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07134998. Target conditions include Advanced KRAS G12D Mutant Solid Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced KRAS G12D Mutant Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07134998 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced KRAS G12D Mutant Solid Tumors